Class information for:
Level 1: ROYAL FREE HIV MED//CD4 CELL COUNT//X BICHAT MED

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
2951 2028 33.0 73%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
26 34435 ANTIRETROVIRAL THERAPY//HIV//NEVIRAPINE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ROYAL FREE HIV MED Address 29 36% 3% 64
2 CD4 CELL COUNT Author keyword 7 17% 2% 37
3 X BICHAT MED Address 6 80% 0% 4
4 HIV CLINICAL TRIALS Journal 6 11% 3% 53
5 COPENHAGEN HIV PROGRAM Address 6 40% 1% 12
6 UNITAT VIH Address 6 50% 0% 8
7 HIV RNA Author keyword 5 17% 1% 27
8 POTENT ANTIRETROVIRAL THERAPY Author keyword 4 67% 0% 4
9 HIV 1 RNA Author keyword 4 17% 1% 23
10 HIV 1 RNA LEVELS Author keyword 4 75% 0% 3

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CD4 CELL COUNT 7 17% 2% 37 Search CD4+CELL+COUNT Search CD4+CELL+COUNT
2 HIV RNA 5 17% 1% 27 Search HIV+RNA Search HIV+RNA
3 POTENT ANTIRETROVIRAL THERAPY 4 67% 0% 4 Search POTENT+ANTIRETROVIRAL+THERAPY Search POTENT+ANTIRETROVIRAL+THERAPY
4 HIV 1 RNA 4 17% 1% 23 Search HIV+1+RNA Search HIV+1+RNA
5 HIV 1 RNA LEVELS 4 75% 0% 3 Search HIV+1+RNA+LEVELS Search HIV+1+RNA+LEVELS
6 TRIZIVIR 4 75% 0% 3 Search TRIZIVIR Search TRIZIVIR
7 CD4 LYMPHOCYTE COUNT 4 15% 1% 24 Search CD4+LYMPHOCYTE+COUNT Search CD4+LYMPHOCYTE+COUNT
8 GESIDA 3 57% 0% 4 Search GESIDA Search GESIDA
9 PLASMA HIV RNA 3 43% 0% 6 Search PLASMA+HIV+RNA Search PLASMA+HIV+RNA
10 VIROLOGICAL FAILURE 3 19% 1% 15 Search VIROLOGICAL+FAILURE Search VIROLOGICAL+FAILURE

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CUBIC MILLIMETER 90 38% 9% 186
2 CD4 CELL COUNTS 36 28% 5% 109
3 HAART REGIMEN 33 77% 1% 23
4 PLUS INDINAVIR 33 45% 3% 54
5 CD4 CELL COUNT 27 24% 5% 99
6 EUROSIDA 24 49% 2% 36
7 INDINAVIR 22 14% 7% 147
8 VIROLOGICAL FAILURE 22 17% 6% 117
9 VIROLOGICAL TREATMENT FAILURE 21 61% 1% 22
10 ZIDOVUDINE PLUS LAMIVUDINE 17 72% 1% 13

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 HIV CLINICAL TRIALS 6 11% 3% 53

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel 2000 732 54 56%
Antiretroviral treatment of adult HIV infection - 2008 recommendations of the International AIDS Society USA panel 2008 623 94 24%
Treatment for adult HIV infection - 2006 recommendations of the International AIDS Society-USA panel 2006 499 76 32%
Outcomes for Efavirenz versus Nevirapine-Containing Regimens for Treatment of HIV-1 Infection: A Systematic Review and Meta-Analysis 2013 12 30 57%
An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults 2006 139 36 67%
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis 2013 24 35 26%
Antiretroviral treatment for adult HIV infection in 2002 - Updated recommendations of the international AIDS Society-USA panel 2002 497 120 26%
Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel 1998 582 34 56%
A Review of the Virological Efficacy of the 4 World Health Organization-Recommended Tenofovir-Containing Regimens for Initial HIV Therapy 2012 19 28 46%
The history of antiretroviral therapy and of its implementation in resource-limited areas of the world 2012 27 74 30%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ROYAL FREE HIV MED 29 36% 3.2% 64
2 X BICHAT MED 6 80% 0.2% 4
3 COPENHAGEN HIV PROGRAM 6 40% 0.6% 12
4 UNITAT VIH 6 50% 0.4% 8
5 EUROSIDA COORDINATING 4 44% 0.3% 7
6 BASEL HIV 3 43% 0.3% 6
7 LONDON SPECIALISED COMMISSIONING GRP 3 100% 0.1% 3
8 SERV ENFERMEDADES INFECCIOSAS SIDA 3 100% 0.1% 3
9 HIV EPIDEMIOL BIOSTAT GRP 3 29% 0.4% 9
10 COMPETENCE NETWORK HIV AIDS 3 50% 0.2% 4

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000205423 K65R//TRANSMITTED DRUG RESISTANCE//HIV 1 DRUG RESISTANCE
2 0.0000184570 ADHERENCE//ANTIRETROVIRAL ADHERENCE//ART ADHERENCE
3 0.0000182795 ATAZANAVIR//RITONAVIR//LOPINAVIR
4 0.0000172973 RETENTION IN CARE//ENGAGEMENT IN CARE//HIV CARE CONTINUUM
5 0.0000167827 EFAVIRENZ//CYP2B6//NEVIRAPINE
6 0.0000162608 LOSS TO FOLLOW UP//KNOWLEDGE TRANSLAT UNIT//HLTH ECON EPIDEMIOL OFF
7 0.0000162244 IMMUNE RECONSTITUTION//CLIN MOL RETROVIROL SECT//IMMUNE ACTIVATION
8 0.0000133106 ETRAVIRINE//RILPIVIRINE//TMC125
9 0.0000126098 HIV LATENCY//HIV CURE//HIV 1 LATENCY
10 0.0000120231 HIV INCUBATION DISTRIBUTION//REPORTING DELAY//NONPROGRESSORS